1 in 3 See 75% Fewer Migraine Days Over 84 Weeks With Eptinezumab
A long-term study found that about half of participants who took eptinezumab (sold under the brand name Vyepti) had their ...
Continue with Facebook
Sign up with your email
Become a member to get even more